Mometasonfuroat Al (Mometasone Furoate Ph. Eur.)

Mometasone furoate, the active ingredient in Mometasonfuroat Al, is a corticosteroid presented as a nasal formulation for nasal use. It treats allergic rhinitis and nasal polyps in adults and children.

GNH USA supplies Mometasonfuroat Al as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mometasone furoate is a topical corticosteroid used to manage inflammatory conditions of the nasal passages.

- Allergic rhinitis: reduces nasal congestion, itching and sneezing. - Nasal polyps: decreases polyp size and improves nasal airflow. - Seasonal allergic rhinitis: alleviates symptoms during pollen seasons.

Adverse reactions may occur with nasal administration of mometasone furoate.

Common Side Effects: - Nasal irritation or burning sensation. - Epistaxis (nosebleeds). - Headache. - Altered taste or bitter taste. - Throat irritation. - Dryness of the nasal mucosa.

Serious or Rare Side Effects: - Fungal infection of the nasal passages. - Severe or prolonged nosebleeds. - Vision changes such as cataracts or glaucoma. - Adrenal suppression with systemic absorption. - Anaphylactic or severe allergic reactions. - Nasal septum perforation (rare).

Use of Mometasonfuroat Al requires careful consideration of several safety aspects.

- Prescription only: use under medical supervision. - Hypersensitivity: avoid if known allergy to mometasone or other corticosteroids. - Recent nasal surgery or trauma: postpone use until healing is complete. - Long‑term use: monitor for signs of adrenal suppression or mucosal atrophy. - Concomitant systemic steroids: assess risk of additive corticosteroid effects. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Mometasone furoate may interact with other medicines that affect corticosteroid metabolism or immune response.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) – may increase systemic exposure. - Live intranasal vaccines – reduced efficacy when used concurrently.

Moderate Interactions (Monitor Closely): - Antifungal agents (e.g., fluconazole) – possible modest increase in exposure. - HIV protease inhibitors – may elevate corticosteroid levels. - Systemic corticosteroids – additive immunosuppressive effect. - Antihistamines – may mask early signs of local irritation.